Related Experiment Videos
Alupent syrup: results of a six-month trial in asthmatic children
Insights
Alupent Syrup (metaproterenol sulfate) effectively managed childhood asthma over six months. Long-term use showed significant lung function improvements without developing drug tolerance or adverse effects.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Bronchial asthma is a chronic respiratory condition affecting children.
- Long-term management strategies for pediatric asthma require safe and effective treatments.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of Alupent Syrup (metaproterenol sulfate) in school-age children with bronchial asthma.
- To assess the development of drug tolerance with continuous metaproterenol sulfate use.
Main Methods:
- A six-month clinical trial involving 23 school-age children diagnosed with bronchial asthma.
- Double-blind, placebo-controlled crossover tests were conducted at three intervals.
- Pulmonary function was assessed using Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in one second (FEV1).
Main Results:
- Significant improvements in PEFR and FEV1 were observed after metaproterenol administration.
- No evidence of tolerance to metaproterenol sulfate was found by the study's end.
- The drug was well-tolerated, with no adverse reactions reported during the trial.
Conclusions:
- Alupent Syrup (metaproterenol sulfate) is a safe and effective option for the long-term management of bronchial asthma in children.
- Sustained therapeutic benefits were observed without the development of tolerance.
- The favorable safety profile supports its use in pediatric asthma management.
Abstract:
A six-month clinical trial of Alupent Syrup was conducted in 23 school-age children with bronchial asthma to assess the long-term efficacy and safety of this dosage form of metaproterenol sulfate. At three intervals during the study period, double-bind crossover tests against placebo were performed. Pulmonary function measurements revealed significant improvement in PEFR and FEV, after metaproterenol, and the results obtained at the end of ths study demonstrated that no tolerance to the drug had developed. The absence of adverse reactions attested to the safety of the drug in long-term management of childhood asthma.